▶ 調査レポート

世界のニューカッスル病/感染性気管支炎/感染性ファブリキウス嚢病ワクチン市場(~2028年):ニューカッスル病、感染性気管支炎/感染性滑液包病ワクチン、生ワクチン、ニューカッスル病、感染性気管支炎/感染性滑液包病ワクチン、不活化

• 英文タイトル:Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Market Insights, Forecast to 2028

Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Market Insights, Forecast to 2028「世界のニューカッスル病/感染性気管支炎/感染性ファブリキウス嚢病ワクチン市場(~2028年):ニューカッスル病、感染性気管支炎/感染性滑液包病ワクチン、生ワクチン、ニューカッスル病、感染性気管支炎/感染性滑液包病ワクチン、不活化」(市場規模、市場予測)調査レポートです。• レポートコード:MRC2Q12-19271
• 出版社/出版日:QYResearch / 2022年12月
• レポート形態:英文、PDF、118ページ
• 納品方法:Eメール(納期:3営業日)
• 産業分類:医薬品&医療
• 販売価格(消費税別)
  Single User¥725,200 (USD4,900)▷ お問い合わせ
  Enterprise License¥1,450,400 (USD9,800)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、ニューカッスル病/感染性気管支炎/感染性ファブリキウス嚢病ワクチンのグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。
ニューカッスル病/感染性気管支炎/感染性ファブリキウス嚢病ワクチンのアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。
ニューカッスル病/感染性気管支炎/感染性ファブリキウス嚢病ワクチンの中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。
ニューカッスル病/感染性気管支炎/感染性ファブリキウス嚢病ワクチンのヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。

生産面において、本レポートは2017年から2022年までのニューカッスル病/感染性気管支炎/感染性ファブリキウス嚢病ワクチンの生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別のニューカッスル病/感染性気管支炎/感染性ファブリキウス嚢病ワクチンの売上および2028年までの予測に焦点を当てています。

ニューカッスル病/感染性気管支炎/感染性ファブリキウス嚢病ワクチンのグローバル主要企業には、Boehringer Ingelheim、Beijing Animal Husbandry and Veterinary Research Institute、Harbin Pharm、Qilu Animal Health、MSD、Pulike、Ruipu、Elanco、HPBG、CBM、Shandong Ludu Creatures、Jofunhwa、Obiosh、Yebio、Cevaなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx%の市場シェアを占めています。

ニューカッスル病/感染性気管支炎/感染性ファブリキウス嚢病ワクチン市場は、タイプとアプリケーションによって区分されます。世界のニューカッスル病/感染性気管支炎/感染性ファブリキウス嚢病ワクチン市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年~2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。

【タイプ別セグメント】
ニューカッスル病、感染性気管支炎/感染性滑液包病ワクチン、生ワクチン、ニューカッスル病、感染性気管支炎/感染性滑液包病ワクチン、不活化

【アプリケーション別セグメント】
動物用医薬品、科学研究

【掲載地域】
北米:アメリカ、カナダ
ヨーロッパ:ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋:日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米:メキシコ、ブラジル、アルゼンチン
中東・アフリカ:トルコ、サウジアラビア、UAE

【目次(一部)】

・調査の範囲
- ニューカッスル病/感染性気管支炎/感染性ファブリキウス嚢病ワクチン製品概要
- タイプ別市場(ニューカッスル病、感染性気管支炎/感染性滑液包病ワクチン、生ワクチン、ニューカッスル病、感染性気管支炎/感染性滑液包病ワクチン、不活化)
- アプリケーション別市場(動物用医薬品、科学研究)
- 調査の目的
・エグゼクティブサマリー
- 世界のニューカッスル病/感染性気管支炎/感染性ファブリキウス嚢病ワクチン販売量予測2017-2028
- 世界のニューカッスル病/感染性気管支炎/感染性ファブリキウス嚢病ワクチン売上予測2017-2028
- ニューカッスル病/感染性気管支炎/感染性ファブリキウス嚢病ワクチンの地域別販売量
- ニューカッスル病/感染性気管支炎/感染性ファブリキウス嚢病ワクチンの地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別ニューカッスル病/感染性気管支炎/感染性ファブリキウス嚢病ワクチン販売量
- 主要メーカー別ニューカッスル病/感染性気管支炎/感染性ファブリキウス嚢病ワクチン売上
- 主要メーカー別ニューカッスル病/感染性気管支炎/感染性ファブリキウス嚢病ワクチン価格
- 競争状況の分析
- 企業M&A動向
・タイプ別市場規模(ニューカッスル病、感染性気管支炎/感染性滑液包病ワクチン、生ワクチン、ニューカッスル病、感染性気管支炎/感染性滑液包病ワクチン、不活化)
- ニューカッスル病/感染性気管支炎/感染性ファブリキウス嚢病ワクチンのタイプ別販売量
- ニューカッスル病/感染性気管支炎/感染性ファブリキウス嚢病ワクチンのタイプ別売上
- ニューカッスル病/感染性気管支炎/感染性ファブリキウス嚢病ワクチンのタイプ別価格
・アプリケーション別市場規模(動物用医薬品、科学研究)
- ニューカッスル病/感染性気管支炎/感染性ファブリキウス嚢病ワクチンのアプリケーション別販売量
- ニューカッスル病/感染性気管支炎/感染性ファブリキウス嚢病ワクチンのアプリケーション別売上
- ニューカッスル病/感染性気管支炎/感染性ファブリキウス嚢病ワクチンのアプリケーション別価格
・北米市場
- 北米のニューカッスル病/感染性気管支炎/感染性ファブリキウス嚢病ワクチン市場規模(タイプ別、アプリケーション別)
- 主要国別のニューカッスル病/感染性気管支炎/感染性ファブリキウス嚢病ワクチン市場規模(アメリカ、カナダ)
・ヨーロッパ市場
- ヨーロッパのニューカッスル病/感染性気管支炎/感染性ファブリキウス嚢病ワクチン市場規模(タイプ別、アプリケーション別)
- 主要国別のニューカッスル病/感染性気管支炎/感染性ファブリキウス嚢病ワクチン市場規模(ドイツ、フランス、イギリス、イタリア、ロシア)
・アジア太平洋市場
- アジア太平洋のニューカッスル病/感染性気管支炎/感染性ファブリキウス嚢病ワクチン市場規模(タイプ別、アプリケーション別)
- 主要国別のニューカッスル病/感染性気管支炎/感染性ファブリキウス嚢病ワクチン市場規模(日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア)
・中南米市場
- 中南米のニューカッスル病/感染性気管支炎/感染性ファブリキウス嚢病ワクチン市場規模(タイプ別、アプリケーション別)
- 主要国別のニューカッスル病/感染性気管支炎/感染性ファブリキウス嚢病ワクチン市場規模(メキシコ、ブラジル、アルゼンチン)
・中東・アフリカ市場
- 中東・アフリカのニューカッスル病/感染性気管支炎/感染性ファブリキウス嚢病ワクチン市場規模(タイプ別、アプリケーション別)
- 主要国別のニューカッスル病/感染性気管支炎/感染性ファブリキウス嚢病ワクチン市場規模(トルコ、サウジアラビア)
・企業情報
Boehringer Ingelheim、Beijing Animal Husbandry and Veterinary Research Institute、Harbin Pharm、Qilu Animal Health、MSD、Pulike、Ruipu、Elanco、HPBG、CBM、Shandong Ludu Creatures、Jofunhwa、Obiosh、Yebio、Ceva
・産業チェーン及び販売チャネル分析
- ニューカッスル病/感染性気管支炎/感染性ファブリキウス嚢病ワクチンの産業チェーン分析
- ニューカッスル病/感染性気管支炎/感染性ファブリキウス嚢病ワクチンの原材料
- ニューカッスル病/感染性気管支炎/感染性ファブリキウス嚢病ワクチンの生産プロセス
- ニューカッスル病/感染性気管支炎/感染性ファブリキウス嚢病ワクチンの販売及びマーケティング
- ニューカッスル病/感染性気管支炎/感染性ファブリキウス嚢病ワクチンの主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- ニューカッスル病/感染性気管支炎/感染性ファブリキウス嚢病ワクチンの産業動向
- ニューカッスル病/感染性気管支炎/感染性ファブリキウス嚢病ワクチンのマーケットドライバー
- ニューカッスル病/感染性気管支炎/感染性ファブリキウス嚢病ワクチンの課題
- ニューカッスル病/感染性気管支炎/感染性ファブリキウス嚢病ワクチンの阻害要因
・主な調査結果

Chicken embryos were inoculated with chicken embryos mixed with chicken newcastle virus ii strains and chicken pox virus weak strains, chicken infectious bronchitis virus H120 strains were inoculated with chicken embryos alone, chicken embryo solution and villurionic allantouria membrane were harvested, homogenized in a certain proportion, stabilizer was added, and dried by freezing vacuum.
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Product Name estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key manufacturers of Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine include Boehringer Ingelheim, Beijing Animal Husbandry and Veterinary Research Institute, Harbin Pharm, Qilu Animal Health, MSD, Pulike, Ruipu, Elanco and HPBG, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, sales, revenue, price and gross margin. Major producers’ production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine manufacturers, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine market. Further, it explains the major drivers and regional dynamics of the global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable sales, revenue, price, market share and rank data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Boehringer Ingelheim
Beijing Animal Husbandry and Veterinary Research Institute
Harbin Pharm
Qilu Animal Health
MSD
Pulike
Ruipu
Elanco
HPBG
CBM
Shandong Ludu Creatures
Jofunhwa
Obiosh
Yebio
Ceva
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides sales, revenue and average price forecast data by activity and by application segments based on sales, price, and value for the period 2017-2028.
Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Segment by Activity
Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine, Live
Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine, Inactivated
Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Segment by Application
Veterinary Drug
Scientific Research
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value and sales data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2017 to 2022. Identification of the major stakeholders in the global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2017 to 2028. Evaluation and forecast the market size for Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Boehringer Ingelheim, Beijing Animal Husbandry and Veterinary Research Institute, Harbin Pharm, Qilu Animal Health, MSD, Pulike, Ruipu, Elanco and HPBG, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by activity, by application and by country, sales and revenue for each segment.
Chapter 7: Europe by activity, by application and by country, sales and revenue for each segment.
Chapter 8: Asia Pacific by activity, by application and by country, sales and revenue for each segment.
Chapter 9: Latin America by activity, by application and by country, sales and revenue for each segment.
Chapter 10: Middle East and Africa by activity, by application and by country, sales and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.

レポート目次

1 Study Coverage
1.1 Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Product Introduction
1.2 Market by Activity
1.2.1 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Market Size Growth Rate by Activity, 2017 VS 2021 VS 2028
1.2.2 Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine, Live
1.2.3 Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine, Inactivated
1.3 Market by Application
1.3.1 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Veterinary Drug
1.3.3 Scientific Research
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales Estimates and Forecasts 2017-2028
2.2 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Revenue Estimates and Forecasts 2017-2028
2.3 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales by Region
2.4.1 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales by Region (2017-2022)
2.4.2 Global Sales Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine by Region (2023-2028)
2.5 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Revenue by Region
2.5.1 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Revenue by Region (2017-2022)
2.5.2 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales by Manufacturers
3.1.1 Global Top Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Manufacturers by Sales (2017-2022)
3.1.2 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine in 2021
3.2 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Revenue by Manufacturers
3.2.1 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Revenue by Manufacturers (2017-2022)
3.2.2 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Revenue in 2021
3.3 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Activity
4.1 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales by Activity
4.1.1 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Historical Sales by Activity (2017-2022)
4.1.2 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Forecasted Sales by Activity (2023-2028)
4.1.3 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales Market Share by Activity (2017-2028)
4.2 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Revenue by Activity
4.2.1 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Historical Revenue by Activity (2017-2022)
4.2.2 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Forecasted Revenue by Activity (2023-2028)
4.2.3 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Revenue Market Share by Activity (2017-2028)
4.3 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Price by Activity
4.3.1 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Price by Activity (2017-2022)
4.3.2 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Price Forecast by Activity (2023-2028)
5 Market Size by Application
5.1 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales by Application
5.1.1 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Historical Sales by Application (2017-2022)
5.1.2 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Forecasted Sales by Application (2023-2028)
5.1.3 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales Market Share by Application (2017-2028)
5.2 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Revenue by Application
5.2.1 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Historical Revenue by Application (2017-2022)
5.2.2 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Forecasted Revenue by Application (2023-2028)
5.2.3 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Revenue Market Share by Application (2017-2028)
5.3 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Price by Application
5.3.1 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Price by Application (2017-2022)
5.3.2 Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Price Forecast by Application (2023-2028)
6 North America
6.1 North America Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Market Size by Activity
6.1.1 North America Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales by Activity (2017-2028)
6.1.2 North America Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Revenue by Activity (2017-2028)
6.2 North America Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Market Size by Application
6.2.1 North America Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales by Application (2017-2028)
6.2.2 North America Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Revenue by Application (2017-2028)
6.3 North America Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Market Size by Country
6.3.1 North America Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales by Country (2017-2028)
6.3.2 North America Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Market Size by Activity
7.1.1 Europe Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales by Activity (2017-2028)
7.1.2 Europe Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Revenue by Activity (2017-2028)
7.2 Europe Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Market Size by Application
7.2.1 Europe Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales by Application (2017-2028)
7.2.2 Europe Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Revenue by Application (2017-2028)
7.3 Europe Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Market Size by Country
7.3.1 Europe Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales by Country (2017-2028)
7.3.2 Europe Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Market Size by Activity
8.1.1 Asia Pacific Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales by Activity (2017-2028)
8.1.2 Asia Pacific Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Revenue by Activity (2017-2028)
8.2 Asia Pacific Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Market Size by Application
8.2.1 Asia Pacific Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales by Application (2017-2028)
8.2.2 Asia Pacific Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Revenue by Application (2017-2028)
8.3 Asia Pacific Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Market Size by Region
8.3.1 Asia Pacific Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales by Region (2017-2028)
8.3.2 Asia Pacific Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Market Size by Activity
9.1.1 Latin America Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales by Activity (2017-2028)
9.1.2 Latin America Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Revenue by Activity (2017-2028)
9.2 Latin America Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Market Size by Application
9.2.1 Latin America Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales by Application (2017-2028)
9.2.2 Latin America Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Revenue by Application (2017-2028)
9.3 Latin America Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Market Size by Country
9.3.1 Latin America Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales by Country (2017-2028)
9.3.2 Latin America Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Market Size by Activity
10.1.1 Middle East and Africa Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales by Activity (2017-2028)
10.1.2 Middle East and Africa Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Revenue by Activity (2017-2028)
10.2 Middle East and Africa Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Market Size by Application
10.2.1 Middle East and Africa Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales by Application (2017-2028)
10.2.2 Middle East and Africa Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Revenue by Application (2017-2028)
10.3 Middle East and Africa Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Market Size by Country
10.3.1 Middle East and Africa Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales by Country (2017-2028)
10.3.2 Middle East and Africa Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Boehringer Ingelheim
11.1.1 Boehringer Ingelheim Corporation Information
11.1.2 Boehringer Ingelheim Overview
11.1.3 Boehringer Ingelheim Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Boehringer Ingelheim Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Boehringer Ingelheim Recent Developments
11.2 Beijing Animal Husbandry and Veterinary Research Institute
11.2.1 Beijing Animal Husbandry and Veterinary Research Institute Corporation Information
11.2.2 Beijing Animal Husbandry and Veterinary Research Institute Overview
11.2.3 Beijing Animal Husbandry and Veterinary Research Institute Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Beijing Animal Husbandry and Veterinary Research Institute Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Beijing Animal Husbandry and Veterinary Research Institute Recent Developments
11.3 Harbin Pharm
11.3.1 Harbin Pharm Corporation Information
11.3.2 Harbin Pharm Overview
11.3.3 Harbin Pharm Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Harbin Pharm Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Harbin Pharm Recent Developments
11.4 Qilu Animal Health
11.4.1 Qilu Animal Health Corporation Information
11.4.2 Qilu Animal Health Overview
11.4.3 Qilu Animal Health Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Qilu Animal Health Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Qilu Animal Health Recent Developments
11.5 MSD
11.5.1 MSD Corporation Information
11.5.2 MSD Overview
11.5.3 MSD Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 MSD Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 MSD Recent Developments
11.6 Pulike
11.6.1 Pulike Corporation Information
11.6.2 Pulike Overview
11.6.3 Pulike Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Pulike Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Pulike Recent Developments
11.7 Ruipu
11.7.1 Ruipu Corporation Information
11.7.2 Ruipu Overview
11.7.3 Ruipu Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Ruipu Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Ruipu Recent Developments
11.8 Elanco
11.8.1 Elanco Corporation Information
11.8.2 Elanco Overview
11.8.3 Elanco Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Elanco Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Elanco Recent Developments
11.9 HPBG
11.9.1 HPBG Corporation Information
11.9.2 HPBG Overview
11.9.3 HPBG Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 HPBG Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 HPBG Recent Developments
11.10 CBM
11.10.1 CBM Corporation Information
11.10.2 CBM Overview
11.10.3 CBM Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 CBM Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 CBM Recent Developments
11.11 Shandong Ludu Creatures
11.11.1 Shandong Ludu Creatures Corporation Information
11.11.2 Shandong Ludu Creatures Overview
11.11.3 Shandong Ludu Creatures Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Shandong Ludu Creatures Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Shandong Ludu Creatures Recent Developments
11.12 Jofunhwa
11.12.1 Jofunhwa Corporation Information
11.12.2 Jofunhwa Overview
11.12.3 Jofunhwa Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Jofunhwa Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Jofunhwa Recent Developments
11.13 Obiosh
11.13.1 Obiosh Corporation Information
11.13.2 Obiosh Overview
11.13.3 Obiosh Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Obiosh Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Obiosh Recent Developments
11.14 Yebio
11.14.1 Yebio Corporation Information
11.14.2 Yebio Overview
11.14.3 Yebio Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Yebio Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Yebio Recent Developments
11.15 Ceva
11.15.1 Ceva Corporation Information
11.15.2 Ceva Overview
11.15.3 Ceva Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.15.4 Ceva Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Ceva Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Industry Chain Analysis
12.2 Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Production Mode & Process
12.4 Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales and Marketing
12.4.1 Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Sales Channels
12.4.2 Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Distributors
12.5 Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Industry Trends
13.2 Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Market Drivers
13.3 Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Market Challenges
13.4 Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Market Restraints
14 Key Findings in The Global Newcastle Disease, Infectious Bronchitis and Infectious Bursal Disease Vaccine Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer